Product name as reported
Rosiglitazone: adverse event reports filed with FDA
878 reports list it as a suspect or interacting product, 2004–2025.
- 878
- reports as suspect product
- 0% of all reports · about 40 a year
- 0
- reports, 12 months to June 2026
- 3 in the 12 months before
- 97%
- marked serious by the reporter
- 57.4% across all reports
- 19.2%
- record death among outcomes, as reported
- 169 reports · not verified by FDA
Between July 2004 and May 2025, 878 adverse event reports received by FDA list the product name "Rosiglitazone" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (647) are left out of every figure here.
In the 12 months to June 2026, 0 reports listed it, against 3 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 40 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are cardiac failure congestive (16.7%), myocardial infarction (15.6%) and death (8.2%). A report can list several reactions, so shares add to more than 100%; 187 different terms appear across these reports. Cardiac failure congestive is recorded in 16.7% of these reports, against 0.4% of all reports in the database.
97% of the reports are marked serious by the reporter; 19.2% record death among the outcomes and 48.2% record hospitalisation, as reported. 31.8% of the reports came from physicians, and the largest patient age group is 45 to 64 (31.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Rosiglitazone reports recording the termall reports in the database
- Cardiac failure congestivecongestive heart failure16.7%147
- Myocardial infarctionheart attack15.6%137
- Deaththe patient died; cause not stated by this term8.2%72
- Cerebrovascular accidentstroke6.8%60
- Dyspnoeashortness of breath6.5%57
- Coronary artery disease6.2%54
- Oedema peripheralswelling of the legs, ankles or hands5.7%50
- Drug interactionan interaction between medicines5%44
- High density lipoprotein decreased4.9%43
- Myocardial ischaemia4.6%40
- Cardiovascular disorder4.4%39
- Hypoglycaemialow blood sugar4.3%38
- Condition aggravatedthe condition being treated got worse3.2%28
- Cardiac disorder3%26
- Weight increasedweight gain3%26
- Cardiac failureheart failure2.8%25
- Chest painchest pain2.8%25
- Hypertensionhigh blood pressure2.6%23
- Atrial fibrillationan irregular heart rhythm2.2%19
- Falla fall2.2%19
- Pulmonary oedemafluid in the lungs2.2%19
- Completed suicidedeath by suicide1.9%17
- Hepatic failureliver failure1.7%15
- Oedemaswelling from fluid1.7%15
- Pleural effusionfluid around the lung1.7%15
- Vomitingbeing sick1.7%15
- Loss of consciousnesspassing out1.6%14
- Nauseafeeling sick1.6%14
- Cardio-respiratory arrestthe heart and breathing stopped1.5%13
Top 30 of 187 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 59.8% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Diabetes mellitus | 291 | 33.1% |
| Type 2 diabetes mellitus | 55 | 6.3% |
| Diabetes mellitus non-insulin-dependent | 24 | 2.7% |
| Dementia alzheimer's type | 4 | 0.5% |
| Insulin resistance | 2 | 0.2% |
| Lipoatrophy | 2 | 0.2% |
The indication field is filled in by the reporter and is often blank; shares are of all 878 reports.
In context
| Measure | Rosiglitazone | All reports |
|---|---|---|
| Reports as suspect product | 878 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 97% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 192 | 91 |
| Hospitalisation recorded, per 1,000 reports | 482 | 213 |
| Consumer-filed share | 31.4% | 45.8% |
| Top term, share of reports | Cardiac failure congestive 16.7% | 0.4% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Rosiglitazone reports
How many adverse event reports has FDA received for Rosiglitazone?
878 reports list Rosiglitazone as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 647 list it only as a concomitant medication.
What reactions are recorded in Rosiglitazone reports?
cardiac failure congestive (16.7%), myocardial infarction (15.6%), death (8.2%), cerebrovascular accident (6.8%) and dyspnoea (6.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Rosiglitazone was responsible.
How serious are the reports?
97% are marked serious by the reporter. Among the outcomes recorded, 19.2% of reports include death and 48.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (31.8%), consumer or non-health professional (31.4%) and other health professional (15.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Rosiglitazone rising?
0 reports in the 12 months to June 2026, against 3 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Rosiglitazone was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Rosiglitazone?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Rosiglitazone as a suspect or interacting product; reports listing it only as a concomitant medication (647) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.